Biotron Limited Stock Short Ratio
| BITRF Stock | USD 0.01 0.00 0.00% |
Biotron Limited fundamentals help investors to digest information that contributes to Biotron's financial success or failures. It also enables traders to predict the movement of Biotron Pink Sheet. The fundamental analysis module provides a way to measure Biotron's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biotron pink sheet.
Biotron |
Biotron Limited Company Short Ratio Analysis
Biotron's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Biotron Limited has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The short ratio for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Sectors Now
SectorsList of equity sectors categorizing publicly traded companies based on their primary business activities |
| All Next | Launch Module |
Biotron Fundamentals
| Return On Equity | -1.12 | |||
| Return On Asset | -0.56 | |||
| Profit Margin | (1.78) % | |||
| Operating Margin | (1.78) % | |||
| Current Valuation | 15.31 M | |||
| Shares Outstanding | 901.94 M | |||
| Shares Owned By Insiders | 14.13 % | |||
| Price To Earning | (3.04) X | |||
| Price To Book | 23.61 X | |||
| Price To Sales | 11.17 X | |||
| Revenue | 1.56 M | |||
| Gross Profit | 1.56 M | |||
| EBITDA | (2.73 M) | |||
| Net Income | (2.78 M) | |||
| Cash And Equivalents | 1.74 M | |||
| Total Debt | 77.24 K | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 2.35 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (2.44 M) | |||
| Earnings Per Share | (0) X | |||
| Number Of Employees | 10 | |||
| Beta | -1.2 | |||
| Market Capitalization | 18.67 M | |||
| Total Asset | 1.91 M | |||
| Retained Earnings | (37 M) | |||
| Working Capital | 3 M | |||
| Current Asset | 3 M | |||
| Net Asset | 1.91 M |
About Biotron Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotron Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotron using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotron Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Biotron Pink Sheet
Biotron financial ratios help investors to determine whether Biotron Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotron with respect to the benefits of owning Biotron security.